Clinical trials: Antiviral Agents
Hepatitis C
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
- Trial name
- NCT03402165
- Testing
- Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
- Where
- Egypt
- Volunteers
- 1,200 people
- Sponsor
- Sherief Abd-Elsalam
Chronic Hepatitis B
Safety and Tolerability of TG1050: A Dose-finding Study
Methodology: This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection.
- Trial name
- NCT02428400
- Testing
- TG1050
- Where
- 12 sites in Canada, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Transgene
COVID-19
Inhaled Ivermectin and COVID-19
Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally.
- Trial name
- CCOVID-19 (NCT04681053)
- Testing
- Ivermectin Powder
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Adenovirus
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV)…
- Trial name
- AdAPT (NCT03339401)
- Testing
- Standard of Care, Brincidofovir
- Where
- 36 sites in United States, France and 7 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Hepatitis C Infection
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (what the body does to the medication) and antiviral activity of JNJ-47910382 when administered in different dosing regimens in Caucasian…
- Trial name
- NCT01651767
- Testing
- JNJ-47910382
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Janssen R&D Ireland
CMV Infection
Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration
With the increasing use of letermovir and considering that haploidentical hematopoietic stem cell transplantation (haplo-HSCT) predominates in China alongside a high CMV seroprevalence in the population, multiple domestic centers…
- Trial name
- NCT07443501
- Volunteers
- 1,114 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Hepatitis B
Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy
Patients with Chronic Hepatitis B on long term oral antiviral therapy have to continue treatment indefinitely unless they achieve HBeAg seroconversion or HBsAg seroclearance, when therapy can be stopped.
- Trial name
- SWAP (NCT01928511)
- Testing
- peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly, Nucleos(t)ide analogue therapy
- Where
- 4 sites in Singapore
- Volunteers
- 254 people
- Sponsor
- Seng Gee Lim
Chronic Hepatitis B
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA levels by PCR (log10 copies/mL) at Week 22
- Trial name
- NCT01022801
- Testing
- Entecavir
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Influenza Virus Infection
Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients
This study mainly focused on the effect of early antiviral treatment on the duration of cough in influenza patients.investigators conducted an early investigation of patients with positive influenza virus and asked whether…
- Trial name
- NCT03618407
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Renmin Hospital of Wuhan University
HIV Infections
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
Infection with HIV-1 continues to be a serious health threat throughout the world. Chronic exposure to combination anti-retroviral therapy identified anti-retroviral associated long-term toxicities.
- Trial name
- NCT03784079
- Testing
- GSK3640254
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 34 people
- Sponsor
- ViiV Healthcare
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis B Infection, Malignant Solid Neoplasm
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid…
- Trial name
- NCT03887702
- Testing
- Best Practice, Entecavir, Tenofovir Alafenamide
- Where
- 193 sites in United States, Guam
- Volunteers
- 4 people
- Sponsor
- SWOG Cancer Research Network
HIV Infections
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
- Trial name
- NCT00002337
- Testing
- Vesnarinone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Otsuka America Pharmaceutical
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Human Immunodeficiency Virus 1
A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in…
- Trial name
- NCT00919854
- Testing
- Darunavir, Ritonavir
- Where
- 8 sites in Argentina, Brazil and 3 more
- Volunteers
- 27 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Pregnant Woman, Adult Patient
Investigation of the Passage of Antiviral Antibodies From Mother to Child
Infections remain a major cause of neonatal morbidity and mortality worldwide. At birth, multiple microorganisms, to which they are particularly vulnerable given the immaturity and naïve nature of their immune system, may infect…
- Trial name
- TransAc (NCT05821764)
- Testing
- Blood sample and data collection
- Volunteers
- 4,050 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients
The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain alcohol) when they are given together.
- Trial name
- NCT00002198
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
Hepatitis C, Chronic
Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT02014571
- Testing
- GSK2878175
- Where
- Puerto Rico
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)
The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic…
- Trial name
- NCT03180619
- Testing
- TAF
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 124 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.